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BACKGROUND: We aimed to evaluate the value of inhibin A and PAPP-A2 (pregnancy-associated plasma protein-A2) as novel 
biomarkers in the prediction of preeclampsia-related complications and how they compare with angiogenic biomarkers.
METHODS AND RESULTS: Making use of a secondary analysis of a prospective, multicenter, observational study, intended to 
evaluate the usefulness of sFlt-1 (soluble Fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio, we measured inhi-
bin A and PAPP-A2 levels in 524 women with suspected/confirmed preeclampsia. Women had a median gestational age of 
35 weeks (range, 20–41 weeks) while preeclampsia occurred in 170 (32%) women. Levels of inhibin A and PAPP-A2 were sig-
nificantly increased in women with preeclampsia and in maternal perfusate of preeclamptic placentas. Inhibin A and PAPP-A2 
(C-index = 0.73 and 0.75) significantly improved the prediction of maternal complications when added on top of the traditional 
criteria; gestational age, parity, proteinuria, and diastolic blood pressure (C-index = 0.60). PAPP-A2 was able to improve the 
C-index from 0.75 to 0.77 when added on top of the sFlt-1/PlGF ratio for the prediction of maternal complications. To discrimi-
nate fetal/neonatal complications on top of traditional criteria, inhibin A and PAPP-A2 showed additive value (C-index = 0.79 
to 0.80 and 0.82, respectively) but their discriminative ability remained inferior to that of sFlt-1/PlGF ratio or PlGF. Interestingly, 
the PAPP-A2/PlGF ratio alone showed remarkable value to predict pregnancy complications, being superior to sFlt-1/PlGF 
ratio in the case of maternal complications.
CONCLUSIONS: Inhibin A and PAPP-A2 show significant potential to predict preeclampsia-related pregnancy complications and 
might prove beneficial on top of the angiogenic markers.
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Preeclampsia is a multisystem disorder unique to pregnancy, characterized by the new onset of hypertension and proteinuria, intrauterine growth 
restriction, or evidence of other end-organ damage 
occurring after 20 weeks of gestation.1,2 Affecting 5% 
to 7% of all pregnant women, preeclampsia poses a 
great threat to maternal and fetal well-being world-
wide.3 Because the clinical presentation and course 
of preeclampsia can vary considerably, it remains im-
portant to identify those women at risk for developing 
severe complications such as eclampsia, pulmonary 
edema, hemolysis, elevated liver enzymes, low plate-
let count (HELLP) syndrome, liver and kidney damage, 
along with iatrogenic preterm birth, perinatal morbidity, 
and mortality.4 Since hypertension and proteinuria, the 
classical hallmarks of the disorder, have shown poor 
value to predict adverse outcomes,5 several biochem-
ical markers are emerging to improve diagnostic tools 
applied to women with a clinical suspicion or diagnosis 
of preeclampsia.
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The pathogenesis underlying preeclampsia re-
mains uncertain, although it is well-recognized that 
placental ischemia triggers the release of placental 
factors into the maternal circulation, leading to the 
clinical syndrome of preeclampsia.3 While certain 
placental factors, including the sFlt-1 (soluble Fms-
like tyrosine kinase-1), placental growth factor (PlGF), 
or their ratio have been established as good candi-
date biomarkers for the prediction of preeclampsia 
or adverse outcomes,6,7 other biomarkers are still 
being uncovered. In recent years, the circulating fac-
tors inhibin A and PAPP-A2 (pregnancy-associated 
plasma protein-A2) have emerged as novel biomark-
ers for preeclampsia.8–10 Inhibin A is a glycoprotein 
hormone belonging to the transforming growth fac-
tor family,11 while PAPP-A2 is an insulin growth factor 
(IGF) binding protein protease thought to be involved 
in the regulation of IGF bioavailability8. Both inhibin A 
and PAPP-A2 are abundantly expressed in the pla-
centa, and have been reported to be significantly ele-
vated in the maternal circulation as well as placentas 
of pregnancies complicated by preeclampsia.8,12–15 
Yet, current evidence on the role of these factors 
as biomarkers, particularly for the development of 
preeclampsia-related adverse outcomes remains 
scarce.
We hypothesized that inhibin A and PAPP-A2 could 
be better discriminating markers for the prediction of 
adverse outcome in women with suspected or con-
firmed preeclampsia than the angiogenic markers. 
In this secondary analysis, we examined the value of 
inhibin A and PAPP-A2 as predictors and compared 
their value to that of sFlt-1, PlGF, and sFlt-1/PlGF ratio. 
In addition, we explored their levels in placental perfu-
sate of healthy pregnant women versus women with 
an established diagnosis of preeclampsia.
METHODS
All supporting data are available within the article and 
its online supplemental information.
Study Design and Participants
This was a secondary analysis of a prospective co-
hort study involving women with suspected or con-
firmed preeclampsia enrolled between December 
2013 through April 2016 at 3 Dutch hospitals 
(Erasmus Medical Center, Maasstad Hospital in 
Rotterdam and Reinier de Graaf Hospital in Delft) 
with the aim of evaluating the sFlt-1/PlGF ratio 
for the prediction of preeclampsia-related com-
plications. All subjects provided written informed 
consent to participate in the study, which was 
approved by the local research ethics committee 
(MEC-2013-202). Inclusion and exclusion criteria 
were described previously by Saleh et al.6 Women 
with singleton pregnancies who had a confirmed 
clinical diagnosis of preeclampsia, or had symp-
toms such as hypertension, proteinuria, right 
upper quadrant abdominal pain, severe headache, 
visual disturbances, elevated liver enzymes, or de-
creased platelet count were included in the study. 
Preeclampsia was defined according to the defi-
nition of the International Society for the Study of 
Hypertension in Pregnancy (ISSHP) of 2001 which 
was de novo hypertension (systolic blood pres-
sure of ≥140 and diastolic blood pressure [DBP] 
of ≥90  mm  Hg) and proteinuria (protein-to-creati-
nine ratio ≥30  mg/mmol or ≥300  mg/24  hours or 
2+ dipstick) at or after 20 weeks of pregnancy or 
superimposed preeclampsia defined as chronic 
CLINICAL PERSPECTIVE
What is New?
• This is the first study to investigate inhibin A 
and PAPP-A2 (pregnancy-associated plasma 
protein-A2) as potential biomarkers for adverse 
pregnancy outcome in women with suspected 
or confirmed preeclampsia.
What Are the Clinical Implications?
• PAPP-A2 showed the highest value to predict 
preeclampsia-related pregnancy complications 
when added on top of traditional criteria and 
shows comparable value to that of the angio-
genic markers sFlt-1 (soluble Fms-like tyrosine 
kinase-1), placental growth factor (PlGF), and 
sFlt-1/PlGF ratio.
• PAPP-A2 shows incremental predictive value 
when added on top of the sFlt-1/PlGF ratio, 
while the PAPP-A2/PlGF ratio performed bet-
ter than sFlt-1/PlGF ratio to predict maternal 
complications.
• Future studies are necessary to validate our 
findings and to evaluate whether PAPP-A2 and 
inhibin A can be used in clinical practice.
Nonstandard Abbreviations and Acronyms
DBP diastolic blood pressure
HELLP hemolysis, elevated liver enzymes, 
low platelet count
PAPP-A2 pregnancy associated  
plasma protein-A2
PlGF placental growth factor
sFlt-1 soluble Fms-like tyrosine kinase-1
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hypertension with the new onset of proteinuria or 
sudden increase of blood pressure or appearance 
of thrombocytopenia and increased liver enzymes 
or a sudden increase of proteinuria in patients with 
a preexisting proteinuria. HELLP syndrome was 
defined as hemolysis, elevated liver enzymes and 
low platelet count, in the presence or absence of 
hypertension. Women with only suspicion of preec-
lampsia but without gestational hypertension were 
defined as suspected preeclampsia.
Data Collection
For the analysis of sFlt-1 and PlGF, blood was taken at 
study entry only, and after centrifugation, serum was 
stored at −80°C until analysis. All samples were meas-
ured postpartum to avoid influence on decision mak-
ing of the treating physicians.
Outcome Measures
Patients diagnosed with (partial) HELLP at initial in-
clusion (n=37) were excluded from the calculation 
of maternal complications. Maternal complications 
were defined as the development of 1 of the fol-
lowing after inclusion into the study; (partial) HELLP 
syndrome, eclampsia, pulmonary edema, subcapsu-
lar liver hematoma, cerebral hemorrhage/edema or 
infarction, visual disturbances, placental abruption, 
postpartum hemorrhage (blood loss ≥1000 mL after 
delivery), and acute renal failure (absolute increase 
in the serum creatinine concentration of ≥0.3 mg/dL 
[26.4 µmol/L] from baseline; ≥50% increase in serum 
creatinine; or oliguria with <0.5 mL/kg per hour for a 
period of 6 hours).
Fetal/neonatal complications were defined as ad-
mittance to the neonatal intensive care unit; neonatal 
birth weight <10th percentile according to Perinatal 
Registration, The Netherlands; endotracheal intu-
bation; intraventricular or intracranial hemorrhage; 
other intracerebral abnormalities; development of 
sepsis; respiratory distress syndrome; bronchopul-
monary dysplasia defined as chronic lung disease 
developing in preterm neonates treated with oxygen 
and positive-pressure ventilation, with radiographic 
signs of inflammation and scarring, in need of artifi-
cial ventilation 4 weeks post-partum and at 36 weeks 
postmenstrual age; post-hemorrhagic ventricular dil-
atation; periventricular leukomalacia, necrotizing en-
terocolitis, and fetal or neonatal death. All patients 
(n=524) were used for the calculation of fetal/neona-
tal complications.
Patient demographics, physical examination, lab-
oratory test results, maternal and fetal/neonatal com-
plications (diagnosed by treating physicians) were 
obtained from patient’s electronic medical records and 
ascertained by 2 independent researchers.
Perfusion Studies
Placental perfusate samples were obtained from 
previously conducted placental perfusion experi-
ments in which transplacental drug transfer was 
evaluated. These perfusion experiments were pre-
viously described by Hitzerd et al.16,17 Perfusion ex-
periments were conducted in healthy placentas and 
preeclamptic placentas. In brief, maternal and fetal 
perfusion media consisted of Krebs-Henseleit buffer 
at 37°C, supplemented with heparin (final concentra-
tion; 2500 IU/L) and aerated with 95% O2 - 5% CO2. 
The fetal circulation (closed circuit; flow rate, 6 mL/
minute) was established by cannulating the chorionic 
artery and corresponding vein of an intact cotyledon. 
Maternal circulation (closed circuit; flow rate 12 mL/
minute) was created by placing 4 blunt cannulas in 
the intervillous space. At t  =  0, at a concentration 
of ~10×Cmax, either endothelin receptor antagonists, 
PDE-5 (Phosphodiesterase-5) inhibitor sildenafil, or 
no drug as a control were added to the maternal cir-
culation to verify transfer to the fetal circulation.16,17 
These high concentrations were chosen to prevent 
underestimation of transfer. Samples of the mater-
nal and fetal circulations were taken every 30  min-
utes until the end of the experiment (180 minutes) for 
the determination of biomarker concentrations, and 
stored immediately at −80°C.
Biochemical Measurements
Serum levels of sFlt-1 and PlGF were measured in 524 
samples, using an automated analyzer (Cobas 6000, 
e-module; Roche Diagnostics, Mannheim, Germany), 
as described previously.6 Analysis of sFlt-1 and PlGF 
in placental perfusate was also performed by an au-
tomated analyzer (Cobas 6000, e module; Roche 
Diagnostics, Rotterdam, The Netherlands). ELISAs 
(AL-123 and AL-109) from Ansh Labs, Texas were used 
to determine the levels of inhibin A and PAPP-A2. 
Maternal perfusate was diluted 1:100 for PAPP-A2 and 
1:5 for inhibin A, while fetal perfusate was run undi-
luted. Serum was diluted 1:80 for PAPP-A2 and 1:4 
for inhibin A. Greater dilutions were applied in case 
levels were above the highest standard. The analyti-
cal characteristics of the ELISAs have been published 
elsewhere.18–20 The coefficients of variation for inhibin 
A (determined at concentrations of 101 and 345 pg/
mL) and PAPP-A2 (determined at concentrations of 
1.03 and 3.13 ng/mL) were 4.7% and 3.4% and 4.3% 
and 3.7%, respectively. The samples were masked to 
the personnel running the assays.
Statistical Analysis
Data are reported as median with interquartile range for 
continuous variables and as number with percentage 
for categorical variables. The normality of continuous 
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variables was assessed using the Shapiro-Wilk W test. 
For the comparison of continuous variables between 
>2 groups, 1-way ANOVA or Kruskal-Wallis test in 
the case of non-normal distribution was applied with 
a Dunnett or Bonferroni correction for multiple test-
ing. For the comparison of categorical variables be-
tween ≥2 groups, Fisher exact and X2 (Chi-square) 
were applied. Logistic regression analysis was used 
to study the association between the dichotomous 
outcomes (maternal and fetal/neonatal complications) 
and the novel biomarkers and traditional predictors. 
Traditional predictors concerned gestational age (GA) 
at biomarker measurement, parity, proteinuria (uri-
nary protein-to-creatinine ratio), and DBP. Because 
of a high correlation between systolic blood pressure 
and DBP, systolic blood pressure was not included in 
the model. PAPP-A2 was divided by PlGF to generate 
the PAPP-A2 to PlGF ratio. The markers sFlt-1, PlGF, 
sFlt-1/PlGF ratio, inhibin A, PAPP-A2, and PAPP-A2/
PlGF ratio were assessed either alone or added to the 
traditional predictors, and were assessed in all women 
or women with a GA <37 weeks.
To test the added value of new markers on top 
of the sFlt-1/PIGF ratio (or PlGF) we fitted a logistic 
Table 1. Patient Characteristics According to Clinical Diagnosis
Parameter
Suspected Preeclampsia 
(n=249)
GH 
(n=105)
Preeclampsia/HELLP 
(n=170)
Age, y 31 (27–35) 30 (27–34) 32 (28–36)†
Gestational age, wks 35 (31–38) 36 (34–38) 33 (29–36)*,†
Nulliparous, n (%) 136 (55) 70 (67) 101 (59)
Current smoker, n (%) 16 (7) 6 (6) 7 (4)
Race, n (%)
White 175 (70) 82 (78) 105 (62)†
Black 36 (15) 12 (11) 31 (18)
Other 38 (15) 11(11) 34 (20)
Antihypertensives use, n (%) 51 (21) 29 (28) 100 (59)*,†
History of preeclampsia, n (%) 36 (15) 9 (9) 27 (16)
Preexisting hypertension, n (%) 58 (23) 0 (0)* 39 (23)†
Preexisting proteinuria, n (%) 12 (5) 0 (0) 7 (4)
Clinical findings at time of admission
SBP, mm Hg 130 (120–138) 145 (140–150)* 143 (130–154)*
DBP, mm Hg 82 (75–89) 91 (85–97)* 90 (85–98)*
uPCR, mg/mmol 17 (11–27) 16 (11–21) 57 (36–219)*,†
LD, U/L 178 (159–205) 189 (166–210) 216 (183–279)*,†
ALT, U/L 14 (10–19) 14 (11–18) 19 (12–46)*,†
Creatinine, µmol/L 55 (50–62) 59 (54–66)* 61 (54–72)*
Uric acid, mmol/L 0.27 (0.23–0.32) 0.29 (0.24–0.34) 0.33 (0.27–0.39)*,†
Platelet count, 109/L 238 (188–279) 227 (180–276) 211 (160–254)*,†
sFlt-1, pg/mL 3140 (1834–5207) 4902 (2394–7226)* 5641 (1870–10382)*
PlGF, pg/mL 189 (112–361) 110 (71–211)* 73 (33–132)*,†
sFlt-1/PlGF ratio 18 (6–40) 41 (15–87)* 71 (22–272)*,†
Inhibin A, pg/mL 1165 (595–1965) 1484 (862–2606)* 2248 (1374–4071)*,†
PAPP-A2, ng/mL 151 (75–300) 281 (145–471)* 380 (171–555)a
Pregnancy outcomes
Sex (Male/Female), n (%) 129/120 (52/48) 49/56 (47/53) 91/79 (54/46)
Gestational age at birth, wks 38 (37–40) 38 (37–39) 36 (30–37)*,†
Birth weight, g 3275 (2832–3658) 3140 (2646–3541) 2218 (1158–3173)*,†
Birth weight percentile < 10, n (%) 23 (9) 17 (16) 36 (21)*
Time until delivery, d 19 (9–41) 9 (3–21)* 3 (1–13)*,†
Values are median (interquartile range) or number (%).
ALT indicates alanine aminotransferase; DBP, diastolic blood pressure; GH, gestational hypertension; HELLP, hemolysis, elevated liver enzymes, low platelet 
count; LD, lactate dehydrogenase; PAPP-A2, pregnancy-associated plasma protein-A2; PlGF, placental growth factor; SBP, systolic blood pressure; sFlt-1, 
soluble Fms-like tyrosine kinase-1; and uPCR, urinary protein-to-creatinine ratio.
*indicates comparison with suspected preeclampsia at a significance level of P < 0.05; 
†indicates comparison with gestational hypertension at a significance level of P < 0.05.
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regression model containing sFlt-1/PIGF ratio (or PlGF) 
and a logistic regression model containing both sFlt-1/
PIGF ratio (or PlGF) and either PAPP-A2 or inhibin A. 
PAPP-A2 or inhibin A were considered to have addi-
tional value if the likelihood ratio test comparing both 
models was statistically significant.
To assess the discriminative ability of the prediction 
models we used the C-index, which is equivalent to the 
area under the ROC curve for dichotomous outcomes. 
SPSS Statistics 21 (IBM Corporations) and R Software 
were used for the statistical analysis.
RESULTS
Patient Demographics According to 
Clinical Diagnosis
In this secondary analysis, 524 women with a me-
dian age of 31 (27–35) years were included (Table 1). 
Of these women, 249 (48%) had suspected preec-
lampsia, 105 (20%) had gestational hypertension, 
and 170 (32%) met the clinical criteria for preeclamp-
sia and/or HELLP syndrome. Median GA at inclu-
sion was 35 weeks of which 205 (39%) women were 
<34 weeks. Women with preeclampsia/HELLP syn-
drome displayed higher systolic blood pressure and 
DBP, more proteinuria and higher levels of sFlt-1/PlGF 
ratio in comparison with women only suspected of 
preeclampsia. As expected, women with preeclamp-
sia/HELLP syndrome delivered earlier, while their 
newborns were more premature (GA <34 weeks) and 
had lower birth weight percentiles. In total, 68 mater-
nal complications (in some cases; ≥1 complication) 
developed in 64 (13%) women after inclusion, while 
206 (39%) of all pregnancies had ≥1 fetal/ neonatal 
complications (Table S1).
Inhibin A and PAPP-A2 Levels According 
to Clinical Diagnosis
Women with preeclampsia/HELLP syndrome dis-
played higher levels of inhibin A (2248 [1374–4071] 
versus 1165 [595−1965] pg/mL) and PAPP-A2 (380 
[171–555] versus 151 [75–300] ng/mL) when com-
pared with women only suspected of preeclampsia 
(Table 1 and Figure 1).
Inhibin A and PAPP-A2 levels in Placental 
Perfusate
Eleven healthy and four women with preeclampsia 
were included in the placental studies. Their clinical 
characteristics are depicted in Table  2. All healthy 
women underwent elective caesarean section be-
cause of previous caesarean section. All patients 
with preeclampsia underwent a caesarean section 
because of maternal illness and fetal distress. As 
expected, the placentas from preeclamptic preg-
nancies were born at an earlier GA (<34 weeks) and 
were associated with higher maternal DBP, lower 
birth weight, and lower placental weight. In total, 12 
healthy cotyledons (1 placenta yielded 2 cotyledons) 
were used and perfused with either endothelin re-
ceptor antagonists (n=6), sildenafil (n=3), or no drug 
(n=3). The data on the maternal-to-fetal transfer of 
these drugs have been reported before.16,17 Since no 
difference in biomarker levels was observed between 
the different drugs in the healthy placentas, all re-
sults were combined. Two of the four experiments 
with preeclamptic placentas were stopped after 
90 minutes of perfusion because of fetal-to-maternal 
leakage. As shown in Figure  2, the concentrations 
of inhibin A, PAPP-A2, sFlt-1, and PlGF gradually 
increased with time in the maternal perfusate. The 
biomarkers were not detectable in the fetal perfusate 
(data not shown). The biomarkers PAPP-A2, inhibin 
A, and sFlt-1 showed increased levels in all 4 preec-
lamptic placental perfusates when compared with 
Figure 1. Inhibin A and PAPP-A2 (pregnancy-associated 
plasma protein-A2) levels in 524 women according to clinical 
diagnosis.
GH indicates gestational hypertension; HELLP; hemolysis, 
elevated liver enzymes and low platelets *indicates P<0.05 versus 
the other groups (a, versus suspected preeclampsia; b, versus 
GH); aindicates significance at P<0.05 level when compared with 
suspected preeclampsia; b indicates significance at P<0.05 level 
when compared with GH.
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the healthy placentas. With regard to PlGF, biomarker 
levels were within the low range of levels in healthy 
placentas. Results remained unchanged after adjust-
ment for cotyledon weight (data not shown).
Correlations Between Inhibin A and 
PAPP-A2 with the Angiogenic Markers
Inhibin A and PAPP-A2 were positively correlated with 
sFlt-1 (r=0.51 and r=0.59, respectively) and showed a 
negative correlation with PlGF (r=−0.43 and r=−0.51, 
respectively) (Table S2).
Prediction of Maternal Complications
In univariable analysis, PAPP-A2 showed the high-
est ability to discriminate between women with and 
without maternal complications when compared with 
inhibin A (C-index=0.71 versus 0.69), but was inferior 
to PlGF and sFlt-1/PlGF ratio (Table  3). A combina-
tion of PAPP-A2 divided by PlGF (PAPP-A2/PlGF ratio) 
showed the highest value in univariable analysis to 
predict maternal complications, even when compared 
with the sFlt-1/PlGF ratio. When inhibin A, PAPP-A2 
and PAPP-A2/PlGF ratio were added to a model with 
traditional predictors (traditional model), the C-index 
improved from 0.60 for a model without biomarkers 
to 0.73, 0.75, and 0.76, respectively, in comparison 
with 0.72, 0.73, and 0.77 for sFlt-1, PlGF, and sFlt-1/
Table 2. Characteristics of Healthy and Preeclamptic 
Placentas Used for Determination of Biomarkers in 
Placental Perfusion Studies
Healthy Preeclampsia
No. 11 4
Maternal age, y 34 (28–36) 31 (29–33)
Gestational age, wks, d 39.0 (38.5–39.1) 31.4 (31.2–31.6)
Nulliparity, n 0 3
Current smoker, n 1 0
White, n 6 3
Highest DBP (mm Hg) 80 (73–80) 110 (107–113)
Fetal sex (Male/Female) 5/6 3/1
Birth weight (g) 3580 (3338–3815) 1138 (1119–1228)
Birth weight (centile) 61 (53–85) 3 (0–6)
Placental weight (g) 659 (622–753) 333 (318–341)
Values are median (interquartile range) or number. DBP indicates diastolic 
blood pressure.
Figure 2. Placental perfusate levels of inhibin A (A), PAPP-A2 (pregnancy-associated plasma protein-A2) (B), sFlt-1 (C), and 
placental growth factor (D) on the maternal side in healthy placentas (grey circle) and preeclamptic placentas (orange squares).
PAPP-A2 indicates pregnancy-associated plasma protein-A2; PlGF, placental growth factor; and sFlt-1, soluble Fms-like tyrosine 
kinase-1.
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PlGF ratio. When restricting the univariable analysis 
to women with a GA <37 weeks, the PAPP-A2/PlGF 
ratio showed the highest ability to predict maternal 
complications, followed by PlGF, sFlt-1/PlGF ratio, and 
PAPP-A2 (Table 3). Multivariable analysis in this group 
was not performed, because of the limited number of 
maternal complications. When PAPP-A2 was added 
on top of the sFlt-1/PlGF ratio alone, the C-index sig-
nificantly improved (Table S3).
Prediction of Fetal/Neonatal 
Complications
For the prediction of fetal/neonatal complications, in-
hibin A and PAPP-A2 showed poor discriminative abil-
ity with C-indices of 0.63 and 0.64, but the PAPP-A2/
PlGF ratio yielded a C-index of 0.74. When added on 
top of traditional predictors, the C-index increased 
from 0.79 for the traditional model only, to 0.80, 0.82, 
and 0.83 for inhibin A, PAPP-A2, and PAPP-A2/PlGF 
ratio, respectively. This implies that PAPP-A2 and 
PAPP-A2/PlGF ratio reached a value almost similar to 
that of PlGF and sFlt-1/PlGF ratio (Table 4). Restricting 
the calculations to women with GA <37  weeks im-
proved the predictive value of all biomarkers in mul-
tivariable analysis, with PAPP-A2 and PAPP-A2/PlGF 
ratio reaching the highest value when compared with 
inhibin A (C-index = 0.85 and 0.85 versus 0.81), but not 
when compared with sFlt-1/PlGF ratio (C-index=0.86) 
or PlGF alone (C-index=0.87) (Table 4). Inhibin A had 
added value beyond PIGF in predicting fetal/neonatal 
complications, however, the increase in discriminative 
ability was negligible (Table S4).
DISCUSSION
In this secondary analysis, we evaluated inhibin A 
and PAPP-A2 as novel biomarkers to predict ad-
verse pregnancy outcome in women with suspected 
or confirmed preeclampsia, and compared their pre-
dictive value to that of the established angiogenic 
markers sFlt-1, PlGF, and sFlt-1/PlGF ratio. We found 
that PAPP-A2 showed the highest value of the 2 bio-
markers to predict maternal and fetal/neonatal com-
plications, particularly when added to a model with 
traditional clinical predictors (GA at biomarker meas-
urement, DBP, protein-to-creatinine ratio, and parity). 
Conversely, inhibin A was a relatively weak predic-
tor in univariable analysis but showed additive value 
when added on top of traditional variables for the pre-
diction of maternal complications. When compared 
with the angiogenic markers, PAPP-A2 performed 
nearly as well as the sFlt-1/PlGF ratio in multivariable 
analysis to predict maternal complications, while in 
the case of fetal/neonatal complications the 2 bio-
markers showed a predictive value marginally inferior 
to that of sFlt-1/PlGF ratio or PlGF. Strikingly, when 
we incorporated the ratio of PAPP-A2/PlGF ratio in 
our prediction model, this model performed even 
Table 3. Associations Between Maternal Complications (n=64) and Biomarkers in Women With Suspected or Confirmed 
Preeclampsia Without Hemolysis, Elevated Liver Enzymes, Low Platelet ount Syndrome at Time of Inclusion (n=487) and 
Restricted to GA < 37 weeks (n=309)
Model/biomarker
Univariable Multivariable
Odds Ratio C-Index Odds Ratio C-Index
Traditional model 0.60
sFlt-1 1.9 (1.4–2.5) 0.69 1.9 (1.5–2.5) 0.72
PlGF 0.2 (0.1–0.4) 0.73 0.2 (0.1–0.5) 0.73
sFlt-1/PlGF ratio 5.3 (2.9–9.9) 0.75 5.9 (3.1–11) 0.77
Inhibin A 3.9 (2.0–7.8) 0.69 6.3 (2.9–13) 0.73
PAPP-A2 4.5 (2.3–9.1) 0.71 7.8 (3.6–17) 0.75
PAPP-A2/PlGF ratio 5.9 (2.9–12) 0.76 6.4 (3.1–13) 0.76
GA at inclusion < 37 wks (n=309) Odds Ratio C-index
sFlt-1 1.9 (1.4–2.5) 0.70
PlGF 0.1 (0.0–0.4) 0.80
sFlt-1/PlGF ratio 5.6 (2.9–11) 0.80
Inhibin A 5.4 (2.2–13) 0.74
PAPP-A2 10 (3.5–25) 0.79
PAPP-A2/PlGF ratio 18 (7.0–48) 0.85
Traditional model consists of gestational age at time of biomarker measurement, parity, diastolic blood pressure and proteinuria at inclusion. Multivariable 
includes traditional model with one of the biomarkers. Interquartile odds ratio and associated 95% CI was calculated to aid interpretation of continuous 
predictors. It is defined as comparing the risk of maternal complications at the 75th percentile of the marker value versus the 25th percentile. GA indicates 
gestational age; PlGF, placental growth factor; PAPP-A2, pregnancy-associated plasma protein-A2; and sFlt-1, soluble Fms-like tyrosine kinase-1.
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better (univariable analysis), if not similar (multivari-
able analysis) to the sFlt-1/PlGF ratio to predict ma-
ternal complications, whereas for predicting fetal/
neonatal complications, PAPP-A2/PlGF ratio showed 
similar value to that of PlGF or sFlt-1/PlGF ratio in 
multivariable analysis.
Few studies have been performed to investigate 
inhibin A and PAPP-A2 as biomarkers, while most of 
them focused on preeclampsia diagnosis rather than 
adverse pregnancy outcome. For inhibin A, its predic-
tive value has mostly been studied in early pregnancy, 
around 11 to 18  weeks of gestation. Whereas some 
studies reported a weak value of inhibin A as a bio-
marker for preeclampsia diagnosis,21–23 others have 
shown area under the curve values ranging between 
0.71 and 0.79, suggesting it was a relatively good pre-
dictor, either alone or in the presence of other maternal 
biomarkers.10,24 Yet, inhibin A remained inferior to sFlt-1 
and PlGF, in agreement with our observations.10,21,24 
PAPP-A2 has been studied less extensively than inhibin 
A, although it has gained increasing interest over the 
past years. Early studies reported elevated PAPP-A2 
levels both before and during the clinical onset of pre-
eclampsia,8,25 which we were able to confirm in a larger 
cohort of women. Consequently, previous studies 
hypothesized that PAPP-A2 could be a potential bio-
marker in women with preeclampsia to predict adverse 
outcomes, and to our knowledge we are the first to 
investigate this concept.
When we limited our analysis to women with GA 
<37 weeks, the predictive value of the novel biomarkers 
substantially increased, with PAPP-A2 and PAPP-A2/
PlGF ratio showing the highest increase in C-index, 
suggesting that PAPP-A2 might be a better predic-
tive biomarker when measured earlier in pregnancy. 
In a study by Kramer et al.,13 placental expression of 
PAPP-A2 was downregulated in the second trimester 
of healthy pregnancy, which might explain the higher 
predictive value when PAPP-A2 is elevated. Likewise, 
circulating inhibin A levels have shown to remain rel-
atively low in the second trimester of a healthy preg-
nancy.26 Because of the limited number of maternal 
complications, we were unable to investigate whether 
this was also true for women with GA <4 weeks.
To further establish the etiology of these biomark-
ers, we measured their levels along with those of 
sFlt-1 and PlGF in maternal and fetal placental perfu-
sate. While none of the biomarkers were detectable 
in fetal perfusate, the biomarkers sFlt-1, inhibin A, 
and PAPP-A2 were all elevated in the maternal per-
fusate of preeclamptic placentas in comparison with 
healthy placentas. This demonstrates that these bio-
markers originate maternally, and that their synthesis 
is upregulated in preeclampsia. Median serum levels 
of these biomarkers during preeclampsia amount up 
to ≈5641 (range, 696–83  967)  pg/mL, 2248 (range, 
48–21  696)  pg/mL, and 380 (range, 16–3024) ng/
mL for sFlt-1, inhibin A, and PAPP-A2, respectively 
Table 4. Associations Between Fetal/Neonatal Complications and Biomarkers in All Women (n=524) and Restricted for GA 
<37 Weeks (n=343)
Model/biomarker
Univariable Multivariable
Odds Ratio C-Index Odds Ratio C-Index
Traditional model 0.79
sFlt-1 1.9 (1.5–2.4) 0.65 1.9 (1.5–2.6) 0.81
PlGF 0.1 (0.0–0.2) 0.77 0.2 (0.0–0.3) 0.83
sFlt-1/PlGF ratio 2.2 (1.8–2.8) 0.74 2.2 (1.6–2.9) 0.83
Inhibin-A 1.6 (1.3–1.9) 0.63 1.6 (1.2–2.0) 0.80
PAPP-A2 2.2 (1.5–3.2) 0.64 4.9 (2.9–8.3) 0.82
PAPP-A2/PlGF ratio 2.8 (2.1–3.5) 0.74 2.3 (1.8–3.1) 0.83
GA at inclusion < 37 wks (n=343)
Traditional model 0.78
sFlt-1 2.5 (1.8–3.5) 0.70 2.7 (1.8–4.2) 0.83
PlGF 0.0 (0.0–0.1) 0.83 0.1 (0.0–0.1) 0.87
sFlt-1/PlGF ratio 3.9 (2.5–6.4) 0.80 4.3 (2.4–7.6) 0.86
Inhibin A 2.1 (1.5–2.8) 0.68 2.1 (1.5–3.1) 0.81
PAPP-A2 4.2 (2.6–6.8) 0.70 10 (5–21) 0.85
PAPP-A2/PlGF ratio 5.6 (3.5–9.1) 0.80 4.6 (2.7–7.9) 0.85
Traditional model consists of gestational age at time of biomarker measurement, parity, diastolic blood pressure and proteinuria at inclusion. Multivariable 
includes traditional model with one of the biomarkers. Interquartile odds ratio and associated 95% CI was calculated to aid interpretation of continuous 
predictors. It is defined as comparing the risk of fetal/neonatal complications at the 75th percentile of the marker value vs the 25th percentile. GA indicates 
gestational age; PAPP-A2, pregnancy-associated plasma protein-A2; PlGF, placental growth factor; and sFlt-1, soluble Fms-like tyrosine kinase-1.
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(Table 1). When comparing our cotyledon effluent lev-
els with these levels (Figure 2), it is likely that placental 
release of these 3 biomarkers has contributed to the 
increased biomarker levels in the maternal circulation 
during preeclampsia. The >99% drop of sFlt-1 after 
birth confirms this view.27
As expected, maternal perfusate levels of PlGF were 
not elevated nor markedly reduced in preeclamptic pla-
centas when compared with healthy placentas, indicat-
ing its downregulation in preeclampsia is predominantly 
caused by additional factors such as the binding of ex-
cess circulating sFlt-1. Importantly, caution is granted 
when interpreting these findings, since the number 
of preeclamptic placentas remains relatively small. 
Moreover, it was not possible to match these placen-
tas for gestational age, which might affect the effluent 
levels observed. However, this reflects the reality that 
successfully perfusing preterm placentas, particularly 
from preeclamptic patients, remains extremely difficult.
The fact that both inhibin A and PAPP-A2 were 
also positively correlated with sFlt-1 in the mater-
nal circulation, raises the question whether similar 
mechanisms account for their upregulation during 
preeclampsia. Indeed, in a study by Macintire et al.,28 
PAPP-A2 expression in placental explants was sig-
nificantly upregulated during hypoxia, a well-known 
trigger for sFlt-1 synthesis and secretion,3 while an-
other study has shown that inhibin A expression in 
differentiated cytotrophoblasts is upregulated by 
hypoxia-inducible factor.29 Nevertheless, PAPP-A2 
did display added value on top of the sFlt-1/PlGF 
ratio to predict maternal complications, suggesting 
that there may still be additional regulatory mecha-
nisms. Our observation that the PAPP-A2/PlGF ratio 
showed even better value than the sFlt-1/PlGF ratio 
alone to predict maternal complications, also agrees 
with this concept. Hence, these novel biomarkers, 
particularly PAPP-A2, might improve risk prediction 
models in which the sFlt-1/PlGF ratio is already in-
cluded. Comparing the predictive value of PAPP-A2/
PlGF ratio versus the sFlt-1/PlGF ratio is an interest-
ing area for future research.
The present study has limitations. Since this is 
a secondary analysis, future prospective trials are 
necessary to validate our findings. Here, determin-
ing specific thresholds and estimating the sensitivity, 
specificity, negative and positive predictive values of 
these novel biomarkers might be of use to further es-
timate their predictive performance. Also, we were not 
able to assess the predictive value of these biomarkers 
in early pregnancy, since most women were already 
diagnosed with preeclampsia and in ≈60% of women 
blood was taken at ≥34 weeks GA. Lastly, we did not 
perform repeated measurements of the biomarkers 
during pregnancy, which could have given more insight 
into their predictive value.
PERSPECTIVES
Our data illustrate that inhibin A and PAPP-A2 are 
not only good alternate biomarkers for the predic-
tion of adverse pregnancy outcome but could have 
additional value on top of the well-known angio-
genic factors (sFlt-1, PlGF, and their ratio). Moreover, 
combining PAPP-A2 with PlGF (by calculating the 
PAPP-A2/PlGF ratio) might further improve predic-
tion beyond the sFlt-1/PlGF ratio. These findings 
emphasize the need to investigate their value pro-
spectively alone and combined with the established 
angiogenic markers.
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Table S1. Occurrence of adverse maternal outcomes in women without (partial) HELLP at 
time of inclusion (n = 487) and fetal / neonatal outcome in all pregnancies (n = 524).  
 
 
 
Values are number (percentage). Other intracerebral complications include stroke, cysts, 
developmental anomalies, meningitis and vasculopathy. HELLP syndrome indicates hemolysis, 
elevated liver enzymes, low platelet count; NICU indicates neonatal intensive care unit. 
 
 
 
 
Parameter n (%) 
Maternal Complication  
Eclampsia 0 (0) 
(Partial) HELLP syndrome 25 (5) 
Placental abruption 2 (0.4) 
Pulmonary edema 3 (0.6) 
Renal insufficiency 2 (0.4) 
Visual disturbances 2 (0.4) 
Postpartum hemorrhage 34 (7) 
All women with 1 or more complication 64 (13) 
Fetal / Neonatal Complication  
Admission to NICU 135 (26) 
Endotracheal intubation 38 (7) 
Birth weight percentile <10 76 (15) 
Intraventricular hemorrhage 5 (1) 
Intracranial hemorrhage 1 (0.2) 
Other intracerebral abnormalities 8 (2) 
Sepsis 38 (7) 
Respiratory distress syndrome 64 (12) 
Bronchopulmonary dysplasia 11 (2) 
Posthemorrhagic ventricular dilatation 1 (0.2) 
Periventricular leukomalacia 3 (0.6) 
Necrotizing enterocolitis 1 (0.2) 
Fetal or neonatal death 20 (4) 
All pregnancies with 1 or more complication 206 (39) 
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Table S2. Correlations between inhibin A and PAPP-A2 with the angiogenic markers. 
 
Biomarker sFlt-1 PlGF sFlt-1/PlGF ratio 
Inhibin A 0.512* - 0.426* 0.540* 
PAPP-A2 0.590* - 0.510* 0.633* 
 
sFlt-1 indicates soluble Fms-like tyrosine kinase-1; PlGF, placental growth factor; PAPP-A2, 
pregnancy associated plasma protein-A2. *P<0.01. 
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Table S3. Value of inhibin A and PAPP-A2 on top of sFlt-1/PlGF ratio to predict maternal 
complications in all women without HELLP syndrome at time of inclusion (n = 487). 
 
Biomarkers 
Univariable  
Odds Ratio 
C-index 
Multivariable 
Odds Ratio 
C-index P-Value 
sFlt-1/PlGF ratio 5.3 (2.9 - 9.9) 0.75 3.7  (1.9 - 7.4)  0.0001 
Inhibin A 3.9 (2.0 - 7.8) 0.69 2.2 (1.0 - 4.8) 0.76 0.10 
     
   
sFlt-1/PlGF ratio 5.3 (2.9 - 9.9) 0.75 3.4 (1.6 - 7.2)   0.0001 
PAPP-A2 4.5 (2.3 - 9.1) 0.71 2.1 (0.9 - 4.9) 0.77 0.01 
 
Multivariable includes sFlt-1/PlGF ratio with either inhibin A or PAPP-A2. Interquartile odds ratio 
and associated 95% confidence interval was calculated to aid interpretation of continuous predictors.  
It is defined as comparing the risk of maternal complications at the 75th percentile of the marker 
value versus the 25th percentile. sFlt-1 indicates soluble Fms-like tyrosine kinase-1; PlGF,  placental 
growth factor; PAPP-A2, pregnancy associated plasma protein-A2. 
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Table S4. Value of inhibin A and PAPP-A2 to predict fetal/neonatal complications on top of 
PlGF in in all women (n = 524). 
 
 
 
 
 
Multivariable includes PlGF with either inhibin A or PAPP-A2. Interquartile odds ratio and 
associated 95% confidence interval was calculated to aid interpretation of continuous predictors.  
It is defined as comparing the risk of fetal/neonatal complications at the 75th percentile of the marker 
value versus the 25th percentile. sFlt-1 indicates soluble Fms-like tyrosine kinase-1; PlGF,  placental 
growth factor; PAPP-A2, pregnancy associated plasma protein-A2. 
 
Biomarkers 
Univariable  
Odds Ratio 
C-index 
Multivariable 
Odds Ratio 
C-index P-Value 
PlGF 0.1 (0 - 0.2) 0.77 0.1 (0.1 - 0.2)   0.0001 
Inhibin A 1.6 (1.3 - 1.9) 0.63 1.2 (1.0 - 1.5) 0.77 0.04 
            
PlGF 0.1 (0 - 0.2) 0.77 0.1 (0.1 - 0.2)   0.0001 
PAPP-A2 2.2 (1.5 - 3.2) 0.64 0.9 (0.6 - 1.6) 0.77 0.12 
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